Issue 5
-
Phase 2 AMP data provide insight into molecular landscape of lupus
Researchers from the Accelerating Medicines Partnership SLE Consortium reported phase 2 results during a Sunday morning session.
-
Plenary II: Results from six highly anticipated studies reported
During Sunday morning’s Plenary II session, researchers reported results from the VITAL trial, ORAL Surveillance, and STOP-JIA, among others.
-
Gluck lecturer discusses emerging therapies targeting the role of bone in OA
In Sunday’s Oscar S. Gluck, MD Memorial Lecture, Marc Hochberg, MD, MPH, described research into the pathogenesis and progression of OA that has helped identify new targets for therapeutic intervention.
-
ARP lecturer describes link between employment, poverty, and rheumatic diseases
Musculoskeletal conditions, particularly rheumatic diseases like RA and lupus, are among the most common causes of employment problems, according to Edward H. Yelin, PhD, who delivered Sunday’s ARP Distinguished Lecture.
-
FDA representatives provide updates on drug approvals, safety issues
The FDA has been busy during the COVID-19 pandemic, with emergency use authorizations for two rheumatology agents, approvals for new agents, and new indications and safety warnings for both prescription and OTC medications.
-
Experts review diagnostic imaging, treatment options for osteoporosis
During a Monday session, Amanda Crawford, CRNP, CCD, and Saba Mohiuddin, PharmD, BCACP, discussed the management of osteoporosis, with a special focus on diagnostic imaging and pharmaceutical interventions.